Video Workflow-at-a-Glance: NK Cell-Mediated Cytotoxicity Assay
Directly image and count calcein AM-labeled target cells in a 96-well plate using Celigo image cytometer. Concurrent imaging and analysis in 8 minutes.
Video Workflow-at-a-Glance: Seahorse™ Normalization Assay
Celigo Image Cytometer provides a fast, effective, and cell stress-free technique to count cells plated onto uncoated or coated culture plates.
Normalizing Seahorse™ XF Data with Label-Free Cell Counting
How to use Celigo image cytometry to normalize Seahorse™ XF data and eliminate time-consuming protein-based process.
22nd Annual Merck Technology Symposium
Come visit us at booth #413 Merck Technology Symposium 2018 September 5-6, 2018 Ocean Place Resort Long Branch, NJ Posters being presented: High-throughput foci counting of viral titer and antibody neutralization assays using the Celigo Image Cytometer for developing a novel cross-reactive influenza vaccine Long-term time-course monitoring of NK cell-mediated ADCC using the Celigo Image Cytometer A high-throughput 3D tumor spheroid screening method for drug discovery using imaging cytometry
Automated Cell Counters: Accurate, Reproducible Cell Counts for the Entire Cell Therapy Workflow
Cellometer automated cell counters have been facilitating CAR T manufacturing with accurate cell counting and analysis since 2010.
Celigo Provides Image-Based Proof of Single-Cell Clonality
The FDA identifies clonality as one of the most crucial steps in guaranteeing cell line quality and safety. The Celigo Image Cytometer makes single cell sorting easy.
Celigo furthers studies of homologous recombination DNA repair machinery
The Danish Cancer Society Research Center recently published a study furthering their analysis of homologous recombination DNA repair machinery. The group previously reported on a growth factor, PSIP1, that enables DNA end resection. With GFP-transfected U2OS cells, the group investigated a structurally similar protein, hepatoma-derived growth factor-related protein 2 (HDGFRP2). The Celigo analyzed cell number and viability via fluorescent markers. The group reports that HDGRFP2 may help to repair silent genes that have been impaired or active genes inhibited by DNA damage. Read the full publication here.
Celigo evaluates a plant extract for glioblastomoa multiforme treatment
At the Canary Center at Stanford for Early Cancer Detection, investigators studied how AshwaMAX (a steroidal lactone from a winter cherry plant, Withania somnifera, extract) might work as an oral treatment for those with the highly aggressive cancer glioblastoma multiforme (GBM). A heterogeneous disease, non-specific therapies for GBM have proven largely ineffective. Two patient-derived GBM lines (GBM2, GBM39) and one GBM cell line were cultured to create neurospheres that were then exposed to various concentrations of AshwaMAX. Celigo measured cell proliferation and cell death via Trypan Blue staining. AshwaMAX inhibited the neurospheres at nanomolar concentrations. After additional work in vivo, [...]
Cellometer investigates new treatment paradigm for advanced endometrial cancer
University of North Carolina researchers investigated different techniques for inhibiting the catalytic activity of protein hTERT – a marker of advanced stage endometrial cancer. Endometrial cancer cell lines ECC-1 and Ishikawa were exposed to either siRNA or a small molecule pharmacological inhibitor BIBR1532, in addition to the drug paclitaxel, to see whether inhibiting hTERT provided additional efficacy against these cancer cells. The Cellometer, in combination with propidium iodide and Annexin-V FITC, calculated apoptosis in the various treatment conditions. The hTERT inhibition plus paclitaxel did prove synergistic, reducing cell growth and invasion more than paclitaxel alone. Furthermore, BIBR1532 antagonized cell invasion [...]
Celigo Advances studies in T Cell Therapy as a pediatric CHOP patient defeats her recurrent leukemia with immunotherapy
Emily Whitehead, cancer survivor, holding Nexcelom cell counting sheep. Thanks to the lifesaving T cell therapy clinical trial at Children’s Hospital of Philadelphia, Emily Whitehead is now two years cancer free. Diagnosed with acute lymphoblastic leukemia (ALL) right after her 5th birthday, doctors discovered that Emily’s leukemia was particularly resistant to chemotherapy, as are roughly 15% of the total number of ALL cases. After two recurrences of the disease, Emily’s parents enrolled her in a clinical trial for CTL019, an experimental therapeutic using a patient’s own reprogrammed T cells to eliminate the cancer cells. Now 9 years old, [...]